De-risking new cancer therapeutics with *in vitro* platelet assays: comparing the effects of BH3-mimetics on platelet viability

N. Dovlatova, P. Cato, W. Tomlinson, C. Jewell, A. Johnson, E. Rendall, B. Humphries Platelet Services Ltd, Nottingham, UK



## Background

Following the successful development of ABT-199 (Venetoclax) for the treatment of chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML), other BH3-mimetics that target BCL-XL have been investigated to treat solid tumours but have shown on-target and dose-limiting thrombocytopenia (diagram 1)<sup>1,2</sup>.

The PROTAC (Proteolysis Targeting Chimera) DT2216, designed to avoid the on-target platelet toxicity of ABT-263 (Navitoclax, diagram 2), was initially reported to be platelet sparing *in vitro*,<sup>3,4</sup> but later platelet toxicity was reported in mouse, rat and cynomolgus monkey models<sup>5</sup>.

## Conclusion


Using BH3-mimetics with known effects on platelet viability (ABT-199, ABT-263, ABT-737), we have demonstrated the suitability of sensitive, higher throughput *in vitro* platelet assays for predicting *in vivo* platelet toxicity.

Furthermore, in contrast with *in vitro* data in the literature, DT2216 was found to decrease platelet viability and increase caspase 3/7 activity in our *in vitro* platelet toxicity tests. These findings better mirror the early results of *in vivo* studies in animal models.


More sensitive and reliable *in vitro* platelet viability assays are required to better predict *in vivo* toxicity in early drug discovery and development.

Improved *in vitro* cytotoxicity assays with the capability for screening BH3mimetics and other therapeutics in development are available to help de-risk the selection and progression of new drug candidates in drug development.

## **Modes of Action**



**Diagram 1. Summary of the BH3-mimetics and DT2216 and their anti-apoptotic protein targets** The more specific ABT-199 targets BCL-2 only while ABT-737, ABT-263 and DT2216 target BCL-2, BCL-XL and BCL-W.



**Diagram 2. Schematic representing the PROTAC DT2216 interaction with the anti-apoptotic protein target BCL-XL** DT2216 is comprised of a modified ABT-263 warhead, that binds anti-apoptotic proteins, and an E3 ligase ligand. Recruitment of E3 ligase to the target protein leads to the transfer of ubiquitin (Ub) and degradation of the target protein.


## Results

Effects of the compounds ABT-199, ABT-263, ABT-737, and DT2216 were assessed in human washed platelets at 37°C, initially using the MTS assay. A subsequent study was performed with cell titre blue and caspase 3/7 activity assays, as these can be multiplexed.

- The pan-BCL inhibitors ABT-737 and ABT-263 both reduced platelet viability and increased caspase 3/7 activity after 3 h treatment and their
- Although ABT-199 had little to no effect on platelet viability after 3 h, slightly elevated levels of caspase 3/7 activity were observed. A reduction in platelet viability was measured following 24 h treatment and this was corroborated by increased levels of caspase 3/7 activity.

potency increased at 24 h.

- DT2216 was shown to reduce platelet viability and increase caspase 3/7 activity following 24 h incubation.
- The order of potency in cell titre blue and caspase 3/7 activity following 24 h incubation was: ABT-263 > DT2216 = ABT-737 > ABT-199



References: (1) Bcl-x<sub>L</sub>-inhibitory BH3 mimetics (ABT-737 or ABT-263) and the modulation of cytosolic calcium flux and platelet function (S.M. Schoenwaelder & S.P. Jackson 2012). (2) BH3-mimetics: recent developments in cancer therapy (P.A. Townsend et al., 2021), (3) A selective BCL-X<sub>L</sub> PROTAC degrader achieves safe and potent antitumor activity (S. Khan et al., 2019), (4) DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas (Y. He et al., 2020). (5) Discovery of BCL-XL heterobifunctional degrader with potentially improved therapeutic window and minimal platelet toxicity for hematological malignancies (Y. Xie et al., 2023).

www.plateletservices.com l info@plateletservices.com